LawGrids logoLAWGRIDS.ORG

Form MD4, the Medical Device Rules, 2016.: Form MD4

the Medical Device Rules, 2016. - Form MD4

Text of form MD4

Form MD4.

Form MD4. (3) Where any manufacturer intends to manufacture Class C or Class D medical device along with Class A or Class B medical device, an application shall be made to the Central Licensing Authority through an identified online portal of the Central Government for licence to manufacture for sale or for distribution in Form MD4. (4) The application in Form MD4 referred in sub-rule (2), relating to Class A medical devices referred under sub-rule (4) of rule 5, shall be accompanied with a 13 fee as specified in the Second Schedule along with documents specified in clause (i) of Part II of the Fourth Schedule. (5) The application in Form MD3 or Form MD4 referred in sub-rule (1), (2) and (3), relating to Class B, Class C or Class D medical device, as the case may be, shall be accompanied with a fee as specified in the Second Schedule along with documents as specified in clause (ii) of Part II of the Fourth Schedule. (6) The Central Licensing Authority may, wherever required, in case of Class C or Class D medical device, use the services of experts for matters relating to inspection or review of the documents: Provided that the powers and functions under this rule shall be exercised by the Central Licensing Authority till such time the Central Government is satisfied that the requisite technical competence has been acquired by the State Licensing Authority. Loan licence to manufacture for sale and distribution. 16. (1) An application for grant of loan licence to manufacture for sale or distribution of Class A medical device referred under sub-rule (4) of rule 5, or Class B medical devices, as the case may be, shall be made to the State Licensing Authority in Form MD5 accompanied with fee as specified in the Second Schedule along with documents as specified in clause (i) of Part II or clause (ii) of Part II of the Fourth Schedule, as the case may be. (2) An application for grant of loan licence to manufacture for sale or for distribution of Class C or Class D medical devices, as the case may be, shall be accompanied with a fee as specified in the Second Schedule along with documents as specified in clause (ii) of Part II of the Fourth Schedule including details of the constitution of the firm, manufacturing premises plan or layout, full particulars of competent and regular technical staff, artwork of product literature, package insert or instruction for use, proposed device labels, shall be made to the Central Licensing Authority in Form MD6. (3) Where any manufacturer intends to manufacture Class C or Class D medical device along with Class A or Class B medical device, an application for grant of loan licence shall be made as per sub-rule (3) of rule 15 to the Central Licensing Authority in Form MD6. (4) The Central Licensing Authority may, wherever required, in case of Class A, Class B, Class C or Class D medical device, use the services of external agencies or bodies for matters relating to inspection or review of documents. Conditions to be complied before grant of manufacturing licence or loan licence. 17. Before grant of licence or loan licence, the following conditions shall be complied with by the applicant,- (i) Manufacturing activity of medical device shall be undertaken only under the direction and supervision of competent technical staff and who has,- 14 (a) degree in engineering (in appropriate branch) or in pharmacy or in science in appropriate subject and shall have experience of not less than two years; or (b) diploma in engineering (in appropriate branch) or in pharmacy and shall have the experience of not less than four years in manufacturing of medical devices. (ii) The testing shall be conducted under the direction and supervision of the competent technical staff having degree or diploma in engineering in appropriate branch or in pharmacy or in science in appropriate subject and shall have the experience of not less than two years in testing of medical devices. (iii) The manufacturing site shall comply with the requirements of the Fifth Schedule. Audit or inspection before grant of licence for manufacture. 18. Before grant of licence under this part,- (i) in respect of Class A medical device referred under sub-rule (4) of rule 5or Class B medical devices, the establishment where manufacture of such device is proposed to be undertaken shall be audited by the Notified Body; (ii) in respect of Class C or Class D medical devices, the establishment in which the manufacture is or proposed to be undertaken shall be inspected by the Medical Device Officer with or without an expert in the concerned field for adequacy and suitability; Report by Medical Device Officer or Notified Body. 19. (1) The Notified Body shall forward a detailed descriptive report giving findings on each aspect of audit along with recommendations after completion of audit in accordance with the provisions of rule 18, to the State Licensing Authority or Central Licensing Authority, as the case may be, through online portal of the Government referred in rule 15, with a copy to the manufacturer. (2) The Medical Device Officer shall forward a detailed descriptive report giving findings on each aspect of inspection along with recommendations after completion of inspection in accordance with the provisions of rule 18, to the Central Licensing Authority, through online portal of the Central Government referred in rule 15, with a copy to the manufacturer. Grant of licence to manufacture for sale and distribution of medical device. 20. (1) If the State Licensing Authority or the Central Licensing Authority, as the case may be, after such further enquiry, if any, as may be considered necessary, is satisfied that the requirements of these rules have been complied with, it shall issue a licence in Form MD7, or loan licence in Form MD8, as the case may be: Provided that where a manufacturing licence has been granted to any manufacturer under Drugs and Cosmetics Rules, 1945, before the date of commencement of these rules, such manufacturing licence shall be deemed to have been granted as licence under the provision of these rules for the remaining period of the said licence. (2) If the State Licensing Authority or the Central Licensing Authority, as the case may be, is not satisfied, it may reject the application and shall inform the applicant 15 of the reasons in writing for such rejection. Conditions for manufacturing licence or loan licence. 21. After the grant of licence or loan licence, the licence holder shall comply with the following conditions, namely:- (i) licence shall be kept on the approved premises and shall be produced when requested by the Medical Device Officer; (ii) the licence holder shall inform about the occurrence of any suspected unexpected serious adverse event and action taken thereon including any recall to the State Licensing Authority or Central Licensing Authority, as the case may be, within 15 days of such event being brought to the notice of licence holder; (iii) the licence holder shall inform forthwith any major change as specified in the Sixth Schedule to the State Licensing Authority or Central Licensing Authority, as the case may be, for its approval; (iv) the licence holder shall inform forthwith any minor change as specified in the Sixth Schedule to the State Licensing Authority or Central Licensing Authority, as the case may be; (v) the licence holder shall inform the State Licensing Authority or the Central Licensing Authority, as the case may be, in writing within a period of thirty days in the event of change other than change of constitution of the manufacturer or change referred in condition (iii) above. The manufacturer shall submit the confirmation that no changes in specification, labelling or technical staff has been made; (vi) the licence holder shall carry out test of each batch of final product prior to its release for compliance to specification either in his own testing centre or in any accredited testing centre and shall maintain records of such tests for a period of one year after expiry of the medical device; (vii) the licence holder shall, on being informed by the Central Licensing Authority or State Licensing Authority, as the case may be, that any part of any lot of the medical device has been found by the licensing authority not conforming with the provisions specified under the rules and on being directed so to do, withdraw the remainder of that lot from sale and, so far as may, in the particular circumstances of the case, be practicable, recall the issues already made from that lot; (viii) the licence holder shall maintain an audit or inspection book in Form MD9 to enable notified body or medical device officer to record his impressions and the defects noticed; (ix) the licence holder shall maintain at least two units of samples from each batch of the invasive medical device manufactured by him for reference purpose. (x) the license holder shall maintain records of manufacturing and sales which shall be open to inspection by a medical device officer. 16 (xi) the licence holder shall supply the medical device for sale, offer for sale along with its package insert. (xii) in case if the manufacturer has closed down the manufacturing site, the same shall be intimated to the Central Licensing Authority or State Licensing Authority, as the case may be. Fresh Application in case of change in constitution. 22. In case of change in constitution after grant of licence under rule 20, the manufacturer shall make an application under rule 15 for grant of licence within a period of ninety days from the date of such change in constitution: Provided that the existing licence shall be deemed to be valid till such time, a fresh licence is issued or application is rejected by the State Licensing Authority or the Central Licensing Authority, as the case may be. Unannounced audit by State Licensing Authority. 23. The State Licensing Authority shall have at least two per cent. of the cases of licence recommended by every Notified Body annually, audited by its officers, and such cases shall be selected on a random basis. Duration of licence. 24. (1) A licence or loan licence shall remain valid, unless, it is suspended or cancelled, provided the licence holder deposits a licence retention fee as specified in the Second Schedule in every five years from the date of its issue. (2) If the licence holder fails to pay licence retention fee on or before the due date as referred to in sub-rule (1), he shall be liable to pay licence retention fee along with a late fee calculated at the rate of two per cent. of the licence fee for every month or part thereof up to six months, in the event of non-payment of such fee, the licence shall be deemed to have been cancelled. Suspension and cancellation of manufacturing licence. 25. (1) Where the licence holder contravenes any provision of these rules, the State Licensing Authority or the Central Licensing Authority, as the case may be, may, after giving the licence holder an opportunity to show cause why such an order should not be passed, shall by an order in writing including the reasons thereof suspend it for such period as it thinks fit either wholly or in respect of any of the medical device or cancel the licence or loan licence. (2) A licence holder whose licence or loan licence has been suspended or cancelled by the State Licensing Authority or Central Licensing Authority, as the case may be, under sub-rule (1), may within sixty days of the receipt of a copy of the order by him, prefer an appeal to the State Government or Central Government, as the case may be, and State Government or the Central Government, as the case may be, may after giving the licence holder an opportunity of being heard, confirm, reverse or modify such order. (3) Any licence suspended in accordance with these rules shall not be revoked by the State Licensing Authority or the Central Licensing Authority without a detailed written order indicating the reasons for such suspension and the extent of compliance vis-à-vis the deficiencies that led to suspension and publishing the order on its website. 17 (4) All orders of suspension issued or revoked or cancellation of licence shall be duly published on the websites of the State Licensing Authority concerned and the Central Licensing Authority. (5) The State Licensing Authority or the Central Licensing Authority, as the case may be, may order destruction of such stock of medical device in the presence of a Medical Device Officer, if in its opinion, the licence holder has failed to comply with any of the conditions of the licence or loan licence or with any provisions of the Act or rules made thereunder. Product Standards for medical device. 26. The medical devices shall conform to the standards,- (1) laid down by the Bureau of Indian Standards established under section 3 of the Bureau of Indian Standards Act, 1985 (63 of 1985) or the Central Government from time to time; (2) If there is no relevant Standard laid down by the Bureau of Indian Standard or the Central Government, then it shall conform to the standard laid down by International Organisation for Standards (ISO) or other Pharmacopeial standard; (3) In case, national or international standards are not available, the device shall conform to the manufacturer’s standards which are validated. Manufacturing of medical devices for clinical investigation, test, evaluation, examination and demonstration. 27. (1) Small quantity of any class of medical device may be manufactured for the purpose of clinical investigations, test, evaluation, examination, demonstration or training for which an application shall be made in Form MD10 to the Central Licensing Authority and shall be accompanied with a fee as specified in the Second Schedule. (2) On receipt of an application for test licence in the form and manner specified in sub-rule (1) and (2), the Central Licensing Authority shall, on being satisfied, grant the test licence in Form MD11. (3) The licensee shall keep a record of, and shall report to the Central Licensing Authority, the date and quantity of product manufactured under test licence. Duration of licence for clinical investigations, test, analysis, demonstration and training. 28. A licence in Form MD11 shall, unless cancelled earlier, be in force for a period of three years from the date of issue. Cancellation of licence for clinical investigations, test, analysis, demonstration and training 29. (1) Where the licensee contravenes any provision of these rules, the Central Licensing Authority may, after giving him an opportunity in writing, to show cause as to why such an order should not be made, by an order stating the reasons therefor, suspend for such period as he may be deemed proper, or cancel the test licence. (2) Where the licensee is aggrieved by an order made by the Central Licensing Authority under sub-rule (1), he may, within thirty days of the receipt of the order, prefer an appeal to the Central Government and that the Central Government may, after such enquiry as it considers necessary and after affording an opportunity of 18 being heard, issue such order as it may deem proper. Part V Import of Medical Devices Application for issue of licence of overseas manufacturing site and import of medical device. 30. (1) The Central Licensing Authority shall have the powers to grant licence and perform other related functions for import of medical devices specified in sub- rule (1) and (2) of rule 5. (2) An authorised agent having, licence to manufacture for sale or licence to sale by way of wholesale under these rules, shall make an application for import of such medical device to the Central Licensing Authority in Form MD12 for obtain a licence. (3) The application under sub-rule (2) shall be accompanied with fee as specified in the Second Schedule along with documents as specified in the Part I, II, and III of the Fourth Schedule: Provided that any change in the documents submitted at the time of application and prior to grant of licence shall be notified to the Central Licensing Authority. (4) (i) Any subsequent application for grant of licence of additional manufacturing site made by the same authorised agent shall be accompanied with a fee as referred in sub-rule (3); (ii) Any subsequent application for licence of additional medical device made by the same authorised agent shall be accompanied with the fee as specified in the Second Schedule for each medical device; (iii) In case of any subsequent application for grant of licence of different variants of already registered family is made by the same authorised agent, the additional fee as specified in the Second Schedule shall be paid for each variant. (5) A single licence may be granted to an authorised agent in India in respect of one or more medical devices manufactured at one or more manufacturing sites. (6) Where the Central Licensing Authority has a reasonable doubt about the quality of the medical device and decides to subject it to evaluation, test or examination, the fee as charged by concerned testing Centre shall be paid by the authorised agent for such evaluation, test or examination directly to the testing laboratory as specified by the Central Licensing Authority. (7) Where the original licence is defaced, damaged or lost, the authorised agent may make an application accompanied with fee as specified under the Second Schedule for duplicate copy of such licence. Inspection of overseas manufacturing site. 31. The Central Licensing Authority may cause an inspection of the overseas manufacturing site either by itself or by any other person to whom the power has been delegated for the purpose and the applicant shall be liable to pay a fee as specified under the Second Schedule in respect of expenditure required in connection with the visit to the overseas manufacturing site. 19 Grant of licence of medical device and manufacturing site for import. 32. (1) On receipt of an application under sub-rule (2) of rule 30, the Central Licensing Authority shall, on being satisfied about the information and the documents enclosed with the application, grant the licence in Form MD13: Provided that where licence has been granted to the authorised agent before the date of commencement of these rules, such licence certificate shall be deemed to have been granted under the provisions of these rules for the remaining period of the said licence. (2) A licence shall be granted under sub-rule (1) if the medical device is having free sale certificate from the national regulatory authority or competent authority of the United States of America, European Union countries, Canada, Australia and Japan. (3) Where the medical device is proposed to be imported from countries other than those referred to in sub-rule (2), the licence in case of Class C and Class D medical devices may be granted after its safety and effectiveness has been proved or established through clinical investigation in India as specified under Part VII of these rules. Duration of licence. 33. (1) A licence shall remain valid, unless, it is suspended or cancelled, provided the authorised agent deposits a licence retention fee as specified in the Second Schedule for each overseas manufacturing site and for each device in every five years from the date of its issue (2) If the authorised agent fails to pay licence retention fee on or before the due date as referred to in sub-rule (1), he shall be liable to pay licence retention fee along with a late fee calculated at the rate of two per cent. of the licence retention fee for every month or part thereof up to six months and thereafter the licence shall be deemed to have been cancelled. Conditions to be complied with by authorised agent. 34. The licence holder shall comply with the following conditions, namely:- (i) The licence shall be kept and made available in the licensed premises; (ii)The authorised agent shall inform the licensing authority forthwith in the event of any administrative action taken due to adverse reaction, viz. Market withdrawal, regulatory restrictions, cancellation of authorisation or not of standards quality report of any medical device pertaining to this licence declared by the regulatory authority of the country of origin or by any regulatory authority of any other country, where the medical device is marketed, sold or distributed; (iii) The authorised agent in cases referred in condition (ii), shall stop immediately the dispatch and marketing of the medical device; (iv) The Central Licensing Authority after due consideration may issue directions in respect of marketing, sale or distribution of the medical device referred in condition (iii) including withdrawal of medical device from Indian market within a specified time period; (v) The authorised agent shall obtain prior approval from the Central Licensing Authority in case of any change in the intended use or any major change as 20 specified in the Sixth Schedule of medical devices classified under Class B, Class C or Class D; (vi) the authorised shall inform forthwith any minor change as specified in the Sixth Schedule to the State Licensing Authority or Central Licensing Authority, as the case may be; (vii) The authorised agent shall inform the Central Licensing Authority in writing within a period of thirty days in the event of any change in the constitution of the overseas manufacturer or the authorized agent; (viii) Where the Central Licensing Authority is satisfied that the sample of any medical device is not in conformity with the provisions of these rules, it may issue direction for not to sell or offer for sale, or to recall or withdraw, such medical device; (ix) the consignment of medical device shall be accompanied by an invoice or statement showing the name and address of the manufacturer and the name and quantity of medical device. (x) the licence holder shall supply the medical device for sale, offer for sale along with its package insert. Fresh Application in case of change in constitution. 35. In case of change in constitution after grant of licence under rule 32, the importer shall make an application under rule 30 for grant of licence within a period of ninety days from the date of such change in constitution: Provided that the existing licence shall be deemed to be valid till such time, the fresh licence is issued or application is rejected by the Central Licensing Authority. Test licence for import for the purpose of clinical investigations, test, evaluation, demonstration or training 36. (1) Medical device or in vitro diagnostic medical device, the import of which is otherwise not approved, may be allowed by the Central Licensing Authority to be imported in such quantities as may be necessary for the purpose of clinical investigations, test, evaluation, and demonstration or training. (2) The quantity considered necessary shall be determined by the Central Licensing Authority after taking into account the clinical investigation or approved clinical investigation plan or information and documents submitted by the applicant. (3) An application for an import licence for test, evaluation or demonstration or training shall be made to the Central Licensing Authority in Form MD14 and shall be accompanied by the fee as specified in the Second Schedule. (4) On receipt of an application under sub-rule (2), the Central Licensing Authority shall, on being satisfied about the contents and the documents enclosed with the application, grant the test licence in Form MD15. (5) The medical device for which the test licence is granted under sub-rule (4), shall, be used exclusively for purposes of clinical investigation, test, evaluation, demonstration or training, as the case may be, and such clinical investigations, test, evaluation, demonstration or training, shall be conducted in the place specified in 21 such test licence. (6) The holder of test licence shall maintain record of the activities undertaken including the name of manufacturer, quantity imported and date of import. (7) The consignment of medical device shall be accompanied by an invoice or statement showing the name and address of the manufacturer and the name and quantity of medical device. (8) A licence in Form MD15 shall, unless cancelled earlier, be in force for a period of three years from the date of issue. (9) The medical devices including in vitro diagnostic medical device referred in sub-rule (5) that are not used may be permitted to be exported or destroyed under intimation to the Central Licensing Authority. Import of investigational medical device by Government hospital or statutory medical institution for treatment of patient. 37. (1) Small quantity of investigational medical device, the import of which is not allowed, but approved in the country of origin, may be allowed to be imported by the Central Licensing Authority for treatment of a patient suffering from a life threatening disease or disease causing serious permanent disability or disease requiring therapy for unmet medical need, on an application made by the Medical Officer through the medical superintendent of a Government hospital or a statutory medical institution in Form MD16 and such application shall be accompanied by documents required and the fee as specified in the Second Schedule. (2) On receipt of an application under sub-rule (1), the Central Licensing Authority shall, on being satisfied about the information and the documents enclosed with the application, grant the import licence for treatment of patient in Form MD17. (3) The medical device for which the licence is granted under sub-rule (2), shall, be used exclusively for the purpose of treatment of patient declared in the application. (4) The holder of licence shall maintain record of activities undertaken including the name of the manufacturer, quantity imported and used, date of import, name and address of the patient and diagnosis. (5) The holder of licence shall allow the medical device officer authorised by the Central Licensing Authority in this behalf to enter, with or without prior notice, the premises where the medical devices are stocked and to inspect the premises and relevant records and investigate the manner in which the medical device is being used and to take, if required, samples thereof. (6) The quantity considered necessary shall be determined by the Central Licensing Authority after taking into account the treatment of patient suffering from a life threatening disease or disease causing serious permanent disability or disease requiring therapy for unmet medical need (7) Where the Central Licensing Authority is satisfied, it may, in exceptional and special circumstances allow the import of larger quantity of medical devices for use by the patient. 22 (8) The consignment of medical device shall be accompanied by an invoice or a statement showing the name and address of the manufacturer and the name and quantity of medical device. Import of medical device for personal use. 38. (1) Small quantity of medical device, the import of which is not allowed, may be imported for personal use, on an application made by applicant in Form MD18 which shall be accompanied by documents confirming that the device is for legitimate personal use. (2) On receipt of an application under sub-rule (1), the Central Licensing Authority shall, on being satisfied about the information and the documents enclosed with the application, grant permission in Form MD19. (3) The medical device shall be imported subject to the following conditions, namely:- (i) the medical device shall be deemed to be part of the baggage of a passenger or patient and be intended for, the exclusive use of the patient; (ii) the medical device shall be declared as the personal property to the Customs Authorities if they so direct ; (iii) the quantity to be imported is reasonable in the opinion of the Central Licensing Authority; (iv) the medical device is prescribed by a registered medical practitioner; and (v) the consignment of medical device shall be accompanied by an invoice or statement showing the name and address of the manufacturer and the name and quantity of medical device. (4) Where the Central Licensing Authority is satisfied, it may, in exceptional and special circumstances, allow the import of larger quantity of medical devices for use by the patient. Part VI Labelling of Medical Devices Labelling of medical devices. 39. The following particulars shall be printed in indelible ink on the label on the shelf pack of the medical device or on the outer cover of such medical device and on every outer covering in which the medical device is packed, namely:- (a) proper name of medical device; (b) the details necessary for the user to identify the device and its use; (c) the name of the manufacturer and address of the manufacturing premises where the device has been manufactured; (d) the correct statement of the net quantity in terms of weight, measure, volume, number of units, as the case may be, and the number of devices contained in the package, shall be expressed in metric system; and (e) the date of manufacture and date of expiry; alternately the label shall bear the shelf life of the product: Provided that in case of sterile devices, the date of sterilization may 23 be given as the date of the manufacture of the device: Provided further that when the device is made up of materials such as stainless steel or titanium and supplied non-sterile, date of expiry may not be necessary; Explanation: For the purpose of this rule, the date of expiry shall be in terms of month and year and it shall mean the medical device is recommended till the last day of the month. The date of expiry shall be preceded by the words ‘Expiry date’. (f) to provide, wherever required, an indication that the device contains medicinal or biological substance; (g) to provide, a distinctive batch number or lot number preceded by the word “Lot No.” or “Lot” or “Batch No.” or “B. No.”; (h) to indicate, wherever required, any special storage or handling conditions applicable to the device; (i) to indicate, if the device is supplied as a sterile product, its sterile state and the sterilisation method; (j) to give, if considered relevant, warnings or precautions for the attention of the user of the medical device; (k) to label the device, if the device is intended for single use; (l) to overprint on the label of the container, the words “FOR CLINICAL INVESTIGATION ONLY”, if the device is intended for clinical investigation; (m) to overprint on the label of the device, the words “Physician’s Sample- Not to be sold”, if a medical device is intended for distribution to the medical professional as a free sample; (n) to provide, except for imported devices, the manufacturing licence number by preceding the words “Manufacturing Licence Number” or “Mfg. Lic. No.” or “M. L”; (o) devices or In-vitro diagnostics which are not sold to customer or patient directly and are sold for use by hospitals or diagnostic labs shall provide the information affixing additional label or sticker on outer shelf pack; (p) to provide unique device identification of the medical device which shall contain device identifier and production identifier. Explanation: for the purpose of this rule,- (i) “device identifier” means global trade item number. (ii) “production identifier” means serial number, lot or batch number, software as a medical device version, manufacturing and or expiration date. (q) to provide on the label, in case of imported devices, with the approval of the Central Licensing Authority, the import licence number, name and address of the importer and address of the actual manufacturing premises, date of manufacture, (if not already printed at the time of import) may be stickered or overprinted on outer shelf pack: 24 Provided that the label may bear symbols recognised by the Bureau of Indian Standards or International Organisation for Standardization (ISO) in lieu of text and the device safety is not compromised by a lack of understanding on the part of the user in case the meaning of the symbol is not obvious to the device user. Provided that all such medical devices on which the information cannot be printed legibly due to the small size constraints, shall include the information necessary for product identification and safety viz. information covered by clauses (a), (b), (e), (g) and (k) above. Exemption of certain labelling requirements for medical devices for export from India. 40. The labels on packages or container of devices for export shall be adopted to meet the specific requirements of law of the country to which the device is to be exported, but the following particulars shall appear in a conspicuous manner on the label of the inner most pack of the medical device in which the device is packed and every other outer covering in which the container is packed:- (a) name of the Device; (b) the distinctive batch number or lot number preceded by the word “Lot No.” or “Lot” or “Batch No.” or “B.No.”; (c) date of expiry, if any; (d) the name and address of the manufacturer and address of actual premises where the device has been manufactured; (e) licence No. preceded by the letters “Licence No. or Lic. No.”. (f) internationally recognised symbols in lieu of text, wherever required: Provided that where a device is required by the consignee not to be labeled with the name and address of the manufacturer, the label on the packages or container shall bear a code number as approved by the Central Licensing Authority and the code number shall bear the name of the State or Union territory, in abbreviation, followed by the word “Device” and “manufacturing licence number”. Provided further that where a device is required by the consignee not to be labeled with the code number also, the label on the packages or container shall bear a special code number, as requested by the consignee, and approved by the licensing authority. Shelf life of the medical devices. 41. The shelf life of the medical devices shall not exceed sixty months from the date of manufacture: Provided that this period may be extended by the Central Licensing Authority, in respect of any specified medical device, if satisfactory evidence is produced by the manufacturer to justify such extension: Provided that the licensing authority shall not allow the import of any medical device, whose total shelf life claim is less than three months, having less than forty per cent. residual shelf-life period as on the date of import. 25 Provided further that the licensing authority shall not allow the import of any medical device, whose total shelf life claim is between three months and one year, having less than fifty per cent. residual shelf-life period as on the date of import. Provided also that the licensing authority shall not allow the import of any medical device, whose total shelf life claim is more than one year, having less than sixty per cent. residual shelf-life period as on the date of import. Labelling of medical device import or manufactured for purpose of clinical investigations, test, analysis, demonstration and training. 42. Any medical device imported or manufactured, for the purpose of clinical investigations, test, evaluation, demonstration and training, shall be kept in containers bearing labels, indicating name of the product or code number, batch or lot number, date of manufacture, use before date, storage conditions, name and address of the manufacturer, and the purpose for which it has been manufactured. PART VII CLINICAL INVESTIGATION OF MEDICAL DEVICE AND CLINICAL PERFORMANCE EVALUATION OF NEW INVITRO DIAGNOSTIC MEDICAL DEVICE Conduct of clinical investigation. 43. No person or sponsor shall conduct any clinical investigation in respect of investigational medical device in human participants except in accordance with these rules and in accordance with the permission granted by the Central Licensing Authority. Application of Rule 122DD of Drugs and Cosmetics Rules, 1945 with regard of Ethics Committee. 44. (1) The Ethics Committee constituted under rule 122DD of the Drugs and Cosmetics Rules, 1945 shall perform the functions and duties under these rules and shall be deemed to be constituted under these rules. (2) The other provisions of Ethics Committee provided in rule 122DD of the Drugs and Cosmetics Rules, 1945 shall be applicable mutatis mutandis, for the purpose of clinical investigation and clinical performance evaluation under this part. Application for grant of permission to conduct and carry out clinical investigation. 45. (1) An application for grant of permission to conduct clinical investigation for investigational medical device shall be made to the Central Licensing Authority in Form MD20 by a sponsor and shall be accompanied with information specified in the Seventh Schedule: Provided, that the investigational medical devices approved for marketing by United States Food and Drug Administration shall be waived off from the requirements of the clinical investigation under this Part. (2) An application for grant of permission to conduct,- (a) a pilot clinical investigation or first in human study, on an investigational medical device in India shall be made as referred to in sub-rule (1) accompanied with fee as specified in the Second Schedule along with the information as specified in the Seventh Schedule. (b) a pivotal clinical investigation on an investigational medical device shall be made on the basis of data emerging from pilot clinical investigation, as referred in biotech Highlight biotech Highlight biotech Highlight 26 sub-rule (1), accompanied with a fee as specified in the Second Schedule: Provided that no fee shall be paid by any institute, organization, hospital run or funded by the Central Government or State Government, as the case may be, for conduct of clinical investigation. (3) No permission for conduct of academic clinical study on registered or approved medical device shall be required, where,- (a) the investigation is approved by the Ethics Committee; and (b) the data generated shall not be used to furnish it to the Central Licensing Authority for manufacture or import to market investigational medical device in the country. (4) The Central Licensing Authority may, in public interest, abbreviate, defer, or waive the requirement of conducting clinical investigation for reasons to be recorded in writing before granting permission to import or manufacture investigational medical device in the country. (5) Medical device requiring clinical investigation but claiming substantial equivalence to a predicate device shall not be marketed unless the Central Licensing Authority has approved it. Explanation-. For the purposes of this sub-rule, a device shall be deemed to be substantially equivalent in comparison to a predicate device, if it has,- i. the same intended use and technological characteristics; or ii. same intended use and different technological characteristics and demonstrate that the device is as safe and effective as the predicate device; (6) The Central Licensing Authority, after being satisfied with the information furnished along with application under sub-rule (1), may grant permission to conduct clinical investigation for an investigational medical device in Form MD21: Provided that the Central Licensing Authority shall, where the information including clinical investigation is inadequate as per the Seventh Schedule, intimate the applicant in writing, within ninety days from the date of application or such extended period, not exceeding a further period of thirty days, as the Central Licensing Authority may, for reasons to be recorded in writing, permit, the conditions which shall be satisfied before permission could be considered: Provided that if the applicant has not furnished the required information sought by the Central Licensing Authority, within ninety days from the date of intimation, it may reject the application for reasons to be recorded in writing. Condition for permission. 46. After grant of permission referred in rule 45 the following conditions shall be complied with by the applicant,- (i) clinical investigation shall be initiated under the supervision of an approved Ethics Committee; (ii) clinical investigation shall be conducted in compliance with the approved clinical investigation plan, Good Clinical Practices Guidelines and provisions biotech Highlight biotech Highlight biotech Highlight 27 of the Seventh Schedule; (iii) clinical investigation shall be registered with the Clinical Trial Registry of India before enrolling the first patient for such clinical investigation; (iv) annual status report of each clinical investigation, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority by the sponsor, and in case of termination of any clinical investigation, the detailed reasons for the same shall also be communicated to the Central Licensing Authority within thirty days of such termination; (v) information about any report of suspected unexpected serious adverse event occurring during clinical investigation on the subject, shall, after due analysis, be submitted to the Central Licensing Authority within fifteen days of the sponsor coming to know about its occurrence as specified in the Seventh Schedule and in compliance with the procedure specified in these rules. (vi) in case of an injury or death during clinical investigation of the subject of a clinical investigation, the applicant shall provide complete medical management and compensation in case of clinical investigation related injury or death in accordance with these rules. (vii) the premises of the sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical investigation sites shall be open to inspection by officers of Central Licensing Authority or authorised personnel of Notified Bodies under these rules, to verify compliance of the requirements of these rules for conduct of clinical investigation. (viii) the clinical investigation shall be initiated by enrolling first patient within the period of one year from the date of grant of permission, failing which prior permission from the Central Licensing Authority is required. (ix) the Central Licensing Authority may impose any other condition while granting permission in respect of specific clinical investigations, if considered necessary, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of clinical investigation. Suspension or cancellation of permission. 47. (1) If any person to whom permission is granted under this part fails to comply with any of conditions of permission, the Central Licensing Authority may,- (a) issue warning letter giving details of deficiency found; or (b) debar the investigator, sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors to conduct any clinical investigation in future; or (c) suspend the permission for such period as it thinks fit or cancel either wholly or partly to which it relates; biotech Highlight biotech Highlight biotech Highlight biotech Highlight 28 (2) Any person who is aggrieved by the order passed under sub-rule (1), may, within thirty days from the date of receipt of such order, prefer an appeal to the Central Government, and the Central Government may, after such enquiry into the matter, as is considered necessary and after giving an opportunity of being heard, pass such order in relation thereto as, it thinks fit. Medical management and compensation for injury or death related to clinical investigation. 48. (1) Where any participant is injured on account of his participation in the clinical investigation, the sponsor permitted under rule 45 shall provide medical management to that participant. (2) Where an injury is caused to the participant in a clinical investigation of any investigational medical device and such injury is attributable to the use of investigational medical device, the sponsor permitted under rule 45 shall provide to that participant, medical management and such compensation in such manner as specified under rule 122DAB of the Drugs and Cosmetics Rules, 1945 and shall be applicable mutatis mutandis, for the purpose of medical management and such compensation in case of clinical investigation and clinical performance evaluation under this part. (3) Where death of a participant is related to clinical investigation and is attributable to the use of an investigational medical device, the sponsor, permitted under rule 45 shall provide to the legal heir of that participant, such compensation in such manner as specified under rule 122DAB of the Drugs and Cosmetics Rules, 1945 and shall be applicable mutatis mutandis, for the purpose of such compensation in case of clinical investigation and clinical performance evaluation under this part. Power of Medical Devices Officer in respect of clinical investigation or clinical performance evaluation. 49. The Medical Devices Officer, with or without expert, with the prior approval of the Central Licensing Authority may, with or without prior notice, enter into any premises related to clinical investigation or clinical performance evaluation to inspect the facilities, search and seize, record, data, documents, books, and medical devices including investigational medical devices. Maintenance of record and furnishing information. 50. Every person, sponsor, clinical research organisation, any other organisation or investigator conducting a clinical investigation or clinical performance evaluation or his agent holding a permission under this part shall keep and maintain such data, record, registers and other documents for a period of twenty years and shall furnish such information as may be required by the Central Licensing Authority or any other officer authorised by it in this behalf under rule 49. Disclosure of name, address, etc. of persons involved in clinical investigation or clinical performance evaluation. 51. Every person, sponsor, clinical research organisation, any other organisation or investigator conducting a clinical investigation or clinical performance evaluation or his agent, as the case may be, shall, if so required, disclose to the Medical Device Officer or any other officer authorised by the Central Licensing Authority, the names, addresses and other particulars of persons involved in conducting clinical investigation or clinical performance evaluation and similar 29 details in respect of participants in such clinical investigation or clinical performance evaluation. Permission to Conduct of clinical performance evaluation for new in vitro diagnostic medical device 52. (1) No person or sponsor shall conduct any clinical performance evaluation in respect of a new in vitro diagnostic device on specimen, including any blood or tissue donation, derived from the human body except under, and in accordance with, the permission granted by the Central Licensing Authority subject to such conditions and in such form and manner as specified in these rules. (2) An application for grant of permission to conduct, clinical performance evaluation of new in vitro diagnostic device shall be made to the Central Licensing Authority in Form MD22 by the sponsor and shall be accompanied with a fee as specified in the Second Schedule and along with information specified in sub-rule (3)duly signed by the sponsor in India: Provided that no fee shall be required to be paid by the institutes, organizations, hospitals run by the Central Government or State Government, involved in conduct of clinical performance evaluation of new in vitro diagnostic medical devices. (3) The information specified under sub-rule (2) shall contain the following information, namely,- (i) approval from an Ethics Committee, which is registered with the Central Licensing Authority, as prescribed in Appendix VII of the Seventh Schedule; (ii) source and quantity of all types of samples which shall be used during evaluation; (iii) device description including specification of raw material and finished product, data allowing identification of the device in question, proposed instruction for use, labels and regulatory status in other countries, if any; (iv) in house performance evaluation data used to establish stability, specificity, sensitivity, repeatability and reproducibility; (v) clinical performance evaluation plan stating in particular the purpose, scientific, technical or medical grounds, scope of evaluation and number of devices concerned; (vi) Case Report Form as prescribed in Appendix IV of the Seventh Schedule; (vii) Undertaking by investigators as prescribed in Appendix VI of the Seventh Schedule; (viii) the list of laboratories or other institutions taking part in the evaluation study; (ix) the scheduled duration for evaluation and, in case of devices for self- testing, the location and number of lay persons involved; (x) an undertaking that the device in question conforms to the requirements of these rules, apart from aspects covered by the evaluation and apart from biotech Highlight 30 those specifically itemized in the undertaking, and that every precaution has been taken to protect the health and safety of the patient, user and other persons. (4) The Central Licensing Authority may, in public interest, abbreviate, defer, or waive the requirement of conducting clinical performance evaluation for reasons to be recorded in writing for grant of permission to import or manufacture new in vitro diagnostic medical device for marketing. (5) The Central Licensing Authority after being satisfied with the information furnished along with application under sub-rule (1) may grant permission to conduct clinical performance evaluation for anew in vitro diagnostic medical device in Form MD23: Provided where information, as referred to in sub-rule (3) is inadequate, the Central Licensing Authority shall inform the applicant in writing, within ninety days from the date of application or such extended period, not exceeding a further period of thirty days, as the Central Licensing Authority may, for reasons to be recorded in writing, permit, the requirements to be complied with as before permission may be granted: Provided further, if the applicant has not furnished the required information sought by the Central Licensing Authority within ninety days from the date of intimation, it may reject the application for reasons to be recorded in writing. Conditions for permission to conduct of clinical performance evaluation. 53. After grant of permission referred in rule 52, the following conditions shall be complied with by the applicant,- (i) clinical performance evaluation shall be conducted in compliance with the approved clinical performance evaluation plan, Good Clinical Practices Guidelines; (ii) clinical performance evaluation shall be initiated under the supervision of an approved Ethics Committee; (iii) clinical performance evaluation shall be registered with the Clinical Trial Registry of India before enrolling the first patient for such clinical performance evaluation; (iv) annual status report of each clinical performance evaluation, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority by the sponsor, and in case of termination of any clinical performance evaluation, the detailed reasons for the same shall be communicated to the Central Licensing Authority within 30 days of date of termination; (v) the laboratories or other institutions taking part in the evaluation study or the sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical investigation sites shall be open to inspection by officers of the Central Licensing Authority authorised under these 31 rules, to verify compliance of the requirements of these rules for conduct of clinical performance evaluation. (vi) the clinical performance evaluation shall be initiated within the period of one year from the date of grant of permission, failing which prior permission from the Central Licensing Authority shall be required. (vii) the Central Licensing Authority may impose any other condition while granting permission in respect of specific clinical performance evaluation, if considered necessary, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of clinical performance evaluation. Suspension or cancellation of permission. 54. (1) If any person to whom permission is granted under sub-rule (5) of rule 52 fails to comply with any of conditions of permission, the Central Licensing Authority may suspend the permission for such period as it thinks fit or cancel either wholly or partly to which it relates. (2) Any person who is aggrieved by the order passed under sub-rule (1), may within thirty days from the date of receipt of such order, appeal to the Central Government, and the Central Government may, after such enquiry into the matter, as is considered necessary and after giving an opportunity of being heard, pass such order in relation thereto as, it thinks fit. Medical management and compensation for injury related to clinical performance evaluation. 55. Where any participant is injured on account of his participation in the clinical performance evaluation, the sponsor permitted under rule 52 shall provide medical management to that participant. Performance evaluation of in vitro medical devices. 56. (1)The Central Government shall, by notification, designate the Central Government Laboratories or Central medical device testing centres, as the case may be, to carry out performance evaluation in respect of specified in vitro diagnostic medical devices. (2) Performance evaluation prior to grant registration, in respect of in vitro diagnostic medical devices, shall be carried out at the designated laboratories or medical device testing centres under sub-rule (1). (3) Performance evaluation of in vitro diagnostic medical devices shall be carried out as specified by the concerned laboratory or medical device testing centre notified under sub-rule (1). Part VIII Permission to import or manufacture medical device which does not have predicate medical device Permission to import or manufacture medical device of clinical investigation. 57. (1) Save as otherwise provided in these rules for import or manufacture of medical device which does not have predicate medical device or has undergone clinical investigation, an application for grant of permission for such medical device after completion of its clinical investigation or clinical performance evaluation, as the case may be, under Part VII shall be made to the Central Licensing Authority in Form MD24 either by an authorised agent or a manufacturer 32 himself, as the case may be, and shall be accompanied with fee as specified in the Second Schedule along with information specified in Part IV of the Fourth Schedule: Provided medical device which does not have predicate medical device indicated in life threatening, serious diseases or diseases of special relevance to the Indian health scenario, national emergencies, extreme urgency, epidemic and medical devices indicated for conditions, diseases for which there is no therapy, the animal data or clinical data requirements may be abbreviated, deferred or omitted, as deemed appropriate by the Central Licensing Authority: Provided further that subject to other provisions of these rules, in case of medical device of which drugs are also a part, the submission of requirements relating to animal toxicology, reproduction studies, teratogenic studies, perinatal studies, mutagenicity and carcinogenicity may be relaxed in case of drugs already approved and marketed in India and supported by adequate published evidence regarding the safety of the drug. (3) The Central Licensing Authority, after being satisfied, may grant permission to import or manufacture medical device which does not have predicate medical device or has undergone clinical investigation in Form MD25. Permission to import or manufacture new in vitro diagnostic medical device. 58. (1) An application for grant of permission to import or manufacture new in vitro diagnostic medical device shall be made to the Central Licensing Authority in Form MD26 either by an authorised agent or a manufacturer himself, as the case may be, and shall be accompanied with fee as specified in the Second Schedule along with information specified in Part IV of the Fourth Schedule: Provided new in vitro diagnostic medical device indicated in life threatening, serious diseases or diseases of special relevance to the Indian health scenario, national emergencies, extreme urgency, epidemic and medical devices indicated for conditions, diseases for which there is no therapy, the clinical data requirements may be abbreviated, deferred or omitted, as deemed appropriate by the Central Licensing Authority. (3) The Central Licensing Authority, after being satisfied, may grant permission to import or manufacture new in vitro diagnostic medical device in Form MD27. Condition of permission to import or manufacture investigational medical device and new in vitro diagnostic medical device. 59. A permission in Form MD25 or Form MD27 shall be subject to the following conditions, namely:- 33 (1) The medical device shall conform to the specification submitted along with the application; (2) The permission holder shall submit the Periodic Safety Update Report to the Central Licensing Authority from the date of launch in the market and such report shall be submitted every six month for the first two years, followed annually two years submission. (3) The permission holder shall inform the date of launch of medical device in the market to the Central Licensing Authority. (4) The permission holder shall submit the suspected unexpected serious adverse event within fifteen days of the awareness of the event to the Central Licensing Authority. (5) The label, prescribing information or package insert to be adopted for marketing medical device in the country, shall be got approved from the Central Licensing Authority before the medical device is marketed. PART IX Duties and Powers of Medical Device Officer, Medical Device Testing Officer and Notified Body Duties of medical device testing officer. 60. The Medical Device Testing Officer shall cause the sample of medical device or portion thereof tested or evaluated as may be sent in a sealed package by the Medical Device Officer or any other persons under provisions of Part IV, V and VII of these rules and shall furnish the report of the result of the test or evaluation in accordance with these rules. Procedure to be adopted by medical device testing officer on receipt of sample. 61. (1) On receipt of the sealed package of medical device or portion thereof, from a Medical Device Officer or any other persons for test or evaluation, the Medical Device Testing Officer shall compare the seals on the packet or on portion thereof with the specimen impression received separately and shall note the condition of the seals on the packet or on portion thereof. (2) After completion of test or evaluation, the Medical Device Testing Officer shall forthwith furnish a report to the Medical Device Officer in triplicate in Form MD28 of the result of the test or evaluation along with full protocols of the test or evaluation applied. Application for test or evaluation of medical device. 62. For the purpose of these rules, an application from a purchaser for test or evaluation of a medical device or portion of medical device under section 26 of the Act shall be made in Form MD29 and the report of such test or evaluation of the medical device which is prepared on such application shall be supplied to the applicant in Form MD28. Duties of medical device officer. 63. Subject to the instructions of the Central Licensing Authority or State Licensing Authority, as the case may be, it shall be duty of Medical Device Officer to,- (i) inspect not less than once in a year all establishments licensed by the Central Licensing Authority as the case may be, for manufacturing of medical device 34 or State Licensing Authority for sale, distribution, exhibit or offer for sale of medical device, as the case may be, within the area assigned to him; (ii) conform that the conditions of licence are being observed; (iii) take samples of medical device manufactured or imported for sale, or stocked or exhibited for sale in respect of which, the Medical Device Officer has reason to suspect contravention of the provisions of the Act or these rules and send them for test or evaluation: Provided that in case of large sized medical device, where in the opinion of the Medical Device Officer, drawing samples of such a device may not be physically practical, shall be inspected at the same place by the Medical Device Officer with or without expert and evaluated or tested by the Medical Device Testing Officer, for any suspect contravention, after approval of the Central Licensing Authority or State Licensing Authority, as the case may be; (iv) maintain a record of all inspections undertaken, drawing of samples and seizure of stocks and action taken by Medical Device Officer in exercise and performance of duties and to furnish copies of such record to the Central Licensing Authority or State Licensing Authority, as the case may be; (v) make such enquiries and inspections as may be necessary to detect the manufacture or sale of medical device in contravention of any provision of the Act and these rules; (vi) investigate any complaint relating to medical device in writing which may be made to the Medical Device Officer; (vii) institute prosecution in relation to contravention of the provisions of the Act and these rules; (viii) review technical dossier of medical device furnished with the application under these rules or any other duties assigned by the Central Licensing Authority or State Licensing Authority, as the case may be, related to these rules. Prohibition of disclosure of information. 64. Except for the purpose of official business or when required by a Court, a Medical Device Officer shall not, without the sanction in writing of his official superior, disclose to any person any information acquired while exercising such official duties. Form of order not to dispose of stock. 65. An order in writing by a Medical Device Officer under clause (c) of sub-section (1) of section 22 of the Act requiring a person not to dispose of any stock in his possession shall be in Form MD30. Prohibition of sale. 66. No person in possession of a medical device in respect of which a Medical Device Officer has made an order under clause (c) of sub-section (1) of section 22 of the Act shall, in contravention of that order, sell or otherwise dispose of any stock of such medical device. 35 Form of receipt for seized medical devices, record, register, documents or any other material objects. 67. A receipt by a Medical Device Officer for the stock of any medical device or for any record, register, document or any other material object seized under clause (c) or clause (cc) of sub-section (1) of section 22 of the Act shall be in Form MD31. Manner of certifying copies of seized documents. 68. The Medical Device Officer shall return the document, seized under section 22 of the Act, within a period of twenty days from the date of such seizure, to the person from whom they were recovered or produced, after copies thereof or extracts therefrom have been signed by the concerned Medical Device Officer and the person from whom they were recovered or produced. Form of intimation of purpose of taking samples. 69. When a Medical Device Officer takes a sample of a medical device other than medical device specified in proviso to sub-rule (iii) of rule 63 for the purpose of test or evaluation, Medical Device Officer shall inform such purpose in writing in Form MD32 to the person from whom it takes and shall tender the fair price thereof under a written acknowledgement. Form of receipt for samples of medical devices where fair price tendered is refused. 70. Where the fair price tendered under sub-section (1) of section 23 of the Act for sample of medical device or portion thereof taken for the purposes of test or evaluation has been refused by the person from whom such sample has been taken, the Medical Device Officer shall tender a receipt thereof to such person in Form MD33. Procedure for dispatch of sample to medical device testing officer. 71. (1) The sample of medical device or portion thereof sent by Medical Device Officer to the Medical Device Testing Officer for test or evaluation under sub- section (4) of section 23 of the Act shall be sent by registered post or by hand in a sealed packet, enclosed together with a memorandum in Form MD34, in an outer cover addressed to the Medical Device Testing Officer. (2) A copy of the memorandum and a specimen impression of the seal used to seal the packet shall be sent to the Medical Device Testing Officer separately by registered post or handed over by hand and a copy of the memorandum shall be endorsed to the manufacturer. Confiscation of medical devices, implements, machinery, etc. 72. (1) Where any person has been convicted for contravening any of the provisions of the Act or any rule made thereunder, the stock of medical device in respect of which the contravention has been made shall be liable to confiscation. (2) Where any person has been convicted for manufacturing any medical device notified under sub clause (iv) of clause (b) of section 3 of the Act, which is deemed to be misbranded, adulterated or spurious, for sale, stocking or exhibiting for sale or distribution without a valid licence or licence, any implements or machinery used in such manufacture, sale or distribution and any receptable, package or covering in which such medical device is contained and the animals, vehicles, vessels or other conveyances used in carrying such medical device shall be liable to confiscation. Procedure for disposal of confiscated medical device. 73. (1) The Court may refer the confiscated medical device to the Medical Device Officer concerned for report as to whether they are of standard quality or 36 contravene the provisions of the Act or the rules in any respect. (2) If the Medical Device Officer, on the basis of Medical Device Testing Officer’s report, finds the confiscated medical device to be not of standard quality or to contravene any of the provisions of the Act or rules made thereunder, Medical Device Officer shall, with the approval of the Central Licensing Authority or State Licensing Authority, as the case may be, report to the Court accordingly. The Court shall thereupon order destruction of such medical devices. The destruction shall take place under the supervision of the Medical Device

Previous and next

All provisions of the Medical Device Rules, 2016.

Questions people ask

Is form MD4 of the Medical Device Rules, 2016. still in force?

No repeal of the Medical Device Rules, 2016. is recorded.